RxDoctor Payments DataLook up a doctor →

Kenneth Langer, MD

Urology · Baltimore, MDNPI 1356304398

Payments from drug & device makers

$610,141in general payments, 2019–2025

Across 580 payments — averaging $1051.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$400K
  • Checkpoint Surgical, Inc$190K
  • Axonics, Inc.$5K
  • Neotract Inc.$2K
  • Johnson & Johnson$2K
  • Teleflex LLC$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$8444%
  • Travel & lodging$3,14915%
  • Food & beverage$15,46976%
  • Education$8624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610,141 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$378,968
Medicare patients
926
Services billed
8,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide20$284,571
NubeqaDarolutamide17$222,104
MyrbetriqMirabegron164$155,950
XtandiEnzalutamide11$146,178
GemtesaVibegron87$83,708
OrgovyxRelugolix22$53,602
Silodosin48$4,074
Tamsulosin Hcl168$2,913
Finasteride120$2,173
Alfuzosin Hcl ErAlfuzosin Hcl57$1,777
Oxybutynin Chloride ErOxybutynin Chloride62$1,718
Solifenacin Succinate32$1,428
Estradiol18$1,050
Testosterone11$1,031
Dutasteride36$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Xtandi$1,208$302,129175 claims
Johnson & JohnsonErleada$1,561$284,57120 claims
BayerNubeqa$439$222,10417 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,101$137,310109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →